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Propositions / Stellingen
1. The introduction of multi-marker apoptotic tumor phenotypes or- profiles 
into clinical practice is very promising, but demands standardization of 
technical assays and quantification methods. (This thesis)
2. Combined analysis of the level of tumor cell apoptosis and proliferation 
using biochemical assays has great clinical potential towards the 
identification of high-risk stage II colon cancer patients. (This thesis)
3. The p53-SLP® vaccine combined with IFN-α injection is safe and capable 
of inducing p53-specific immunity in humans. (This thesis) 
4. Investigating combined biomarkers related to tumor immune surveillance 
in tumor resection material provides a snapshot of the ongoing process 
of cancer-immunoediting in primary tumors and can be useful to allocate 
adjuvant treatment. (This thesis)
5. The rapid introduction of tumor gene expression-based prognostic tests 
is the perfect example of the restrictive and guiding effect industry has 
on clinical care. 
6. The acknowledgment of cancer immunotherapy as Breakthrough of the 
Year 2013 by Science Magazine is the result of a paradigm shift in how 
the influence of the immune system on tumor growth and development 
is appreciated in cancer research.
7. ‘Molecular science will only get you that far; eventually only paraffin will 
kill all!’ (Donald L. Morton. M.D., Director John Wayne Cancer Institute, 
Santa Monica, California. September 2010, 1934-2014)
8. ‘The patient does not care about your science; what he wants to know is, 
can you cure him?’  (Martin H. Fischer (1879-1962)
9. ‘The most exciting phrase to hear in science, the one that heralds the 
most discoveries, is not “Eureka!” (“I found it!”) but “That’s funny...”’ 
(Isaac Asimov 1920-1992)
10. There is only one strategic plan; it’s called doing things. 
(after Herbert D. Kelleher, former CEO of Southwest Airlines)
11. It is costly wisdom that is bought by experience. (R. Ascham 1515-1568)
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